These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38372710)

  • 21. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts.
    Mueller RB; Hasler C; Popp F; Mattow F; Durmisi M; Souza A; Hasler P; Rubbert-Roth A; Schulze-Koops H; Kempis JV
    J Clin Med; 2019 Sep; 8(10):. PubMed ID: 31561582
    [No Abstract]   [Full Text] [Related]  

  • 22. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
    Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
    Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.
    Tanaka Y; Smolen JS; Jones H; Szumski A; Marshall L; Emery P
    Arthritis Res Ther; 2019 Jul; 21(1):164. PubMed ID: 31277720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
    Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
    PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.
    Li X; Cesta A; Movahedi M; Bombardier C
    Arthritis Res Ther; 2022 Nov; 24(1):255. PubMed ID: 36401335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
    Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
    Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abatacept.
    Bessette L; Haraoui B; Rampakakis E; Dembowy J; Trépanier MO; Pope J
    Arthritis Res Ther; 2023 Sep; 25(1):183. PubMed ID: 37759330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvements in Fatigue Lag Behind Disease Remission in Early Rheumatoid Arthritis: Results From the Canadian Early Arthritis Cohort.
    Holdren M; Schieir O; Bartlett SJ; Bessette L; Boire G; Hazlewood G; Hitchon CA; Keystone E; Tin D; Thorne C; Bykerk VP; Pope JE;
    Arthritis Rheumatol; 2021 Jan; 73(1):53-60. PubMed ID: 32852109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of physical function in early rheumatoid arthritis patients treated with biologics for 1 year who achieved clinical remission or low disease activity.
    Hattori Y; Kida D; Kaneko A
    Clin Rheumatol; 2017 Nov; 36(11):2607-2612. PubMed ID: 28823077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort.
    Movahedi M; Cesta A; Li X; Bombardier C;
    PLoS One; 2022; 17(9):e0274264. PubMed ID: 36070307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry.
    Pappas DA; Blachley T; Zlotnick S; Best J; Emeanuru K; Kremer JM
    Rheumatol Ther; 2020 Jun; 7(2):357-369. PubMed ID: 32232740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Kotb A; Christensen R; Mudano AS; Maxwell LJ; Shah NP; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD012183. PubMed ID: 27175934
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and safety of certolizumab pegol in rheumatoid arthritis patients in Canadian practice: 2-year results from the observational FαsT-CAN study.
    Bessette L; Haraoui B; Chow A; Fortin I; Dixit S; Khraishi M; Haaland D; Elmoufti S; Staelens F; Bogatyreva I; Syrotuik J; Shaikh S
    Ther Adv Musculoskelet Dis; 2019; 11():1759720X19831151. PubMed ID: 30858896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
    Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
    Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
    Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world effectiveness and persistence of reference etanercept versus biosimilar etanercept GP2015 among rheumatoid arthritis patients: A cohort study.
    Carballo N; Pérez García C; Grau S; Monfort J; Durán-Jordà X; Echeverría-Esnal D; Ferrández O
    Front Pharmacol; 2022; 13():980832. PubMed ID: 36263118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry.
    Pappas DA; O'Brien J; Guo L; Shan Y; Baker JF; Kricorian G; Stryker S; Collier DH
    Arthritis Res Ther; 2023 Sep; 25(1):166. PubMed ID: 37689684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.